• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Drug Marketing: Different Impacts on Different Physicians

by Marlene Piturro, PhD, MBA • December 1, 2006

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

The determined pursuit of physicians by PCRs is unsurprising to Brad Marple, MD, of the University of Texas Southwestern Medical School in Dallas. Dr. Marple is an otolaryngologist and AAOA board member (as well as an editorial board member of ENToday). Busy with his clinical practice and students, Dr. Marple has little time for face-to-face visits with PCRs, who frequently visit his office to leave samples. Occasionally, PCRs will leave a peer-reviewed journal article or a chart summarizing a journal article pertinent to an otolaryngology practice. “That is in line with my preferred method of getting information about clinical developments and new medications, which is through peer-reviewed journal articles,” he says. “I approach PCR visits with a jaundiced eye because their job is marketing. Peer-reviewed sources and CME are more regulated,” he adds. He attends professional conferences sponsored by pharmaceutical companies as long as they disclose their interests, checking with the Chicago-based Accreditation Council for Continuing Medical Education (ACCME) if he has questions about a conference’s sponsorship or intent. As for being a “slow” or “fast” learner, Dr. Marple was surprised that companies track physicians in those terms: “For some companies I must be seen as a slow learner and a fast learner by others because the variables by which I’m judging medications are different than what they think is important.”

You Might Also Like

  • When It Comes to Drug Development, What Do Our Dollars Buy?
  • AMA’s Opt-Out Provision for Sale of Physician Prescribing Data Seen as First Step
  • Prescription Drug Benefit Primer
  • Report: Physician Prescribing Behavior Changes Following Restrictions on Direct Marketing
Explore This Issue
December 2006

Dr. Krouse dismisses the notion that prescribing patterns have anything to do with how fast or slow physicians are on the uptake. Rather, he sees colleagues with different prescribing styles: some jump on a new product, some wait for reviews of clinical results, whereas others stick with familiar drugs.

Figure. Some physicians are quick to switch to new drugs, while others stick with those they know.

click for large version
Figure. Some physicians are quick to switch to new drugs, while others stick with those they know.

Official Curbs?

Fortunately, physicians have official allies in keeping PCR behavior and the pharmaceutical industry in check. According to Karen Mahoney, the US Food and Drug Administration’s (FDA’s) trade press liaison, regulations on pharmaceutical sales representatives’ promotions to physicians “should not be false, not be misleading, and should include material facts such as risk information about a prescription.” FDA regulations do not address data collected on prescribing patterns or what gifts may be offered to physicians. Ms. Mahoney suggests that if a physician has a concern about the content of promotion, he or she should contact the FDA’s Division of Drug Marketing, Advertising, and Communications.

That’s what Dr. Krouse recommends for colleagues who have had unpleasant dealings with PCRs and whose complaints to the PCRs’ supervisors haven’t brought about disciplinary action. “Alerting the FDA when a PCR’s message is off label or who makes claims not supported by the label is the right channel for a physician to pursue in such cases,” he says.

Pages: 1 2 3 | Single Page

Filed Under: Departments, Everyday Ethics, Health Policy, Medical Education, Practice Management Tagged With: Ethics, healthcare reform, marketing, medical education, medication, pharmaceuticals, policy, residentsIssue: December 2006

You Might Also Like:

  • When It Comes to Drug Development, What Do Our Dollars Buy?
  • AMA’s Opt-Out Provision for Sale of Physician Prescribing Data Seen as First Step
  • Prescription Drug Benefit Primer
  • Report: Physician Prescribing Behavior Changes Following Restrictions on Direct Marketing

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • Excitement Around Gene Therapy for Hearing Restoration

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Keeping Watch for Skin Cancers on the Head and Neck

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939